K S Beam1, S Aliaga1, S K Ahlfeld2, M Cohen-Wolkowiez3, P B Smith3, M M Laughon4. 1. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Indiana University, Indianapolis, IN, USA. 3. Duke Clinical Research Institute, Durham, NC, USA. 4. 1] Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA [2] Duke Clinical Research Institute, Durham, NC, USA.
Abstract
OBJECTIVE: Bronchopulmonary dysplasia (BPD) is the most common cause of pulmonary morbidity in premature infants and is associated with life-long morbidities. Developing drugs for the prevention of BPD would improve public health. We sought to determine characteristics of favorable randomized controlled trials (RCTs) of drugs for BPD prevention. STUDY DESIGN: We searched MEDLINE and EMBASE from 1992 to 2014 using the MeSH terms 'BPD' and 'respiratory distress syndrome, newborn'. We included a Cochrane Library search to ensure inclusion of all available RCTs. We identified RCTs with BPD as a primary or secondary outcome and determined the definition of BPD used by the study. We determined whether a phase I or phase II study-to determine drug safety, efficacy or optimal dose-was performed before the RCT. Finally, we searched the Cochrane Library for meta-analyses for each drug and used the results of available meta-analyses to define a favorable versus unfavorable RCT. RESULT: We identified 2026 articles; 47 RCTs met our inclusion criteria encompassing 21 drugs; 5 of the drugs reduced the incidence of BPD. We found data from phase I or II studies for 16 of the drugs, but only 1 demonstrated a reduction of BPD. CONCLUSION: The majority of the drugs studied in RCTs failed to reduce the incidence of BPD. Performing early-phase studies before phase III trials might provide necessary information on drugs and drug doses capable of preventing BPD, thus informing the development of future RCTs.
OBJECTIVE: Bronchopulmonary dysplasia (BPD) is the most common cause of pulmonary morbidity in premature infants and is associated with life-long morbidities. Developing drugs for the prevention of BPD would improve public health. We sought to determine characteristics of favorable randomized controlled trials (RCTs) of drugs for BPD prevention. STUDY DESIGN: We searched MEDLINE and EMBASE from 1992 to 2014 using the MeSH terms 'BPD' and 'respiratory distress syndrome, newborn'. We included a Cochrane Library search to ensure inclusion of all available RCTs. We identified RCTs with BPD as a primary or secondary outcome and determined the definition of BPD used by the study. We determined whether a phase I or phase II study-to determine drug safety, efficacy or optimal dose-was performed before the RCT. Finally, we searched the Cochrane Library for meta-analyses for each drug and used the results of available meta-analyses to define a favorable versus unfavorable RCT. RESULT: We identified 2026 articles; 47 RCTs met our inclusion criteria encompassing 21 drugs; 5 of the drugs reduced the incidence of BPD. We found data from phase I or II studies for 16 of the drugs, but only 1 demonstrated a reduction of BPD. CONCLUSION: The majority of the drugs studied in RCTs failed to reduce the incidence of BPD. Performing early-phase studies before phase III trials might provide necessary information on drugs and drug doses capable of preventing BPD, thus informing the development of future RCTs.
Authors: T Ahola; V Fellman; R Laaksonen; J Laitila; R Lapatto; P J Neuvonen; K O Raivio Journal: Eur J Clin Pharmacol Date: 1999-11 Impact factor: 2.953
Authors: Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites Journal: Antimicrob Agents Chemother Date: 2013-02-25 Impact factor: 5.191
Authors: Hubert O Ballard; Lori A Shook; Philip Bernard; Michael I Anstead; Robert Kuhn; Vicki Whitehead; Deb Grider; Timothy N Crawford; Don Hayes Journal: Pediatr Pulmonol Date: 2010-10-20
Authors: Dale L Phelps; Robert M Ward; Rick L Williams; Kristi L Watterberg; Abbot R Laptook; Lisa A Wrage; Tracy L Nolen; Timothy R Fennell; Richard A Ehrenkranz; Brenda B Poindexter; C Michael Cotten; Mikko K Hallman; Ivan D Frantz; Roger G Faix; Kristin M Zaterka-Baxter; Abhik Das; M Bethany Ball; T Michael O'Shea; Conra Backstrom Lacy; Michele C Walsh; Seetha Shankaran; Pablo J Sánchez; Edward F Bell; Rosemary D Higgins Journal: Pediatr Res Date: 2013-09-04 Impact factor: 3.756
Authors: Roberta L Keller; Eric C Eichenwald; Anna Maria Hibbs; Elizabeth E Rogers; Katherine C Wai; Dennis M Black; Philip L Ballard; Jeanette M Asselin; William E Truog; Jeffrey D Merrill; Mark C Mammel; Robin H Steinhorn; Rita M Ryan; David J Durand; Catherine M Bendel; Ellen M Bendel-Stenzel; Sherry E Courtney; Ramasubbareddy Dhanireddy; Mark L Hudak; Frances R Koch; Dennis E Mayock; Victor J McKay; Jennifer Helderman; Nicolas F Porta; Rajan Wadhawan; Lisa Palermo; Roberta A Ballard Journal: J Pediatr Date: 2017-01-16 Impact factor: 4.406
Authors: Brenda B Poindexter; Rui Feng; Barbara Schmidt; Judy L Aschner; Roberta A Ballard; Aaron Hamvas; Anne Marie Reynolds; Pamela A Shaw; Alan H Jobe Journal: Ann Am Thorac Soc Date: 2015-12